Research programme: cyclo-oxygenase-2 inhibitors - FAESAlternative Names: COX-2 inhibitors research programme - FAES; Cyclo-oxygenase-2 inhibitors research programme - FAES; Research programme: COX-2 inhibitors - FAES
Latest Information Update: 23 Mar 2009
At a glance
- Originator FAES Farma
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation